Wednesday, August 5


Manipal Health Enterprises rose sharply in its market debut on Wednesday, valuing India’s largest multispecialty hospital network at about $9.03 billion.

The shares rose as much as ​10.7% to 653.10 rupees on the National Stock Exchange of India, compared with the issue price of 590 rupees. India’s benchmark Nifty was trading 0.06% higher.

The $960 million IPO was ‌India’s second-largest ⁠this year, ⁠behind SBI Funds Management’s listing in July.

Temasek-backed Manipal Health, which operates more than 13,000 ​beds across 49 hospitals, is betting on rapidly growing demand for specialised healthcare options, which ​analysts say will form the bedrock of growth in the Indian healthcare market. The sector is booming with increasing private and foreign investments from ​the likes of Blackstone, Novo Nordisk and KKR.

The ⁠strong listing ‌reflects healthy investor demand, but its premium valuation leaves ​limited upside ​in the near term, said Shivani Nyati, head of wealth ⁠at Swastika Investmart.

“Investors who received the allotment can continue ​to hold the stock, while fresh investors should wait ​for better entry levels or signs of further debt reduction before buying,” Nyati said.

Apollo Hospitals, Manipal Health’s closest listed rival with a market capitalisation of around 1.3 trillion rupees, has nearly 10,000 beds and aims to expand its capacity to 13,000 beds by fiscal 2030.

Max Healthcare and Fortis ‌Healthcare have a market cap of 1.04 trillion rupees and 704.22 billion rupees, respectively.

Manipal Health plans to spend 40 billion ​rupees to ​increase its bed capacity ⁠by over 18% in the next few years, adding 2,400 beds within three to four years.

The company is valued at 84.65 times its fiscal 2026 ​earnings at the upper end of the IPO price band of 560 rupees to 590 rupees, brokerage Angel One said in a note. Apollo, Fortis and Max Healthcare are valued between 66.15x and 74.55x.

  • Published On Aug 5, 2026 at 03:03 PM IST

Join the community of 2M+ industry professionals.

Subscribe to Newsletter to get latest insights & analysis in your inbox.

All about ETHealthworld industry right on your smartphone!




Source link

Share.
Leave A Reply

Exit mobile version